​Boehringer Inglheim Named to Science Magazine’s Top Employer List​

From Boehringer Ingelheim Pharmaceuticals:

Boehringer Ingelheim announced today that it has been named a top employer in the pharmaceutical and biotechnology industry by Science magazine. The Company was listed among only 20 companies, noting its performance in areas such as financial strength, easy adaptation to change and a research-driven environment.

“We are honored to have been recognized on this prestigious list for the twelfth year running,” said Dr. Paige Mahaney, head, Research and Small Molecule Discovery, U.S., Boehringer Ingelheim Pharmaceuticals, Inc. “At Boehringer Ingelheim, we are deeply committed to giving our employees unique opportunities to work on truly cutting-edge scientific research both internally and with our distinguished partners, as well as creating an environment where they feel supported and valued. By fostering an inspiring and collaborative culture, we believe we are better equipped to work toward our ultimate goal – achieving better outcomes for patients.”

The ranking is based on a survey of leaders from the biotechnology, biopharmaceutical, pharmaceutical and related industries. In the annual survey, respondents were asked to rate companies on 23 characteristics. Survey responses were then analyzed by The Brighton Consulting Group, which used a mathematical process to assign a unique score to rate each company’s employer reputation. Each company received a ranking, for example, on the basis of whether it treats its employees with respect, whether its work-culture values align with employees’ personal values and other factors.

As a privately held company, Boehringer Ingelheim is able to take a long-term approach to research and development (R&D), which enables the Company to create a stable and consistent environment for investing in the development of novel medicines to address unmet needs. This vision is supported by significant levels of investment in human pharmaceutical R&D, including a planned investment of around 11 billion euros in international research and development over the next five years.

Image via Shutterstock